95 related articles for article (PubMed ID: 26835709)
1. High BMI and low HDL-C predict the chemotherapy-related hepatic dysfunction in Chinese advanced NSCLC patients.
Lv Y; Ding XS; Li Y; An X; Miao LY
Cancer Biomark; 2016; 16(1):89-97. PubMed ID: 26835709
[TBL] [Abstract][Full Text] [Related]
2. Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy.
Fujiwara Y; Kiura K; Hotta K; Tabata M; Takigawa N; Tanimoto M
Lung Cancer; 2007 Mar; 55(3):343-8. PubMed ID: 17140694
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study.
Luo F; Zeng KM; Cao JX; Zhou T; Lin SX; Ma WJ; Yang YP; Zhang ZH; Lu FT; Huang Y; Zhao HY; Zhang L
Lipids Health Dis; 2021 Sep; 20(1):109. PubMed ID: 34544437
[TBL] [Abstract][Full Text] [Related]
4. [Impact of anemia on chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer].
Xu C; Gao Y; Li L; Xing L; Liu S
Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):968-74. PubMed ID: 20959070
[TBL] [Abstract][Full Text] [Related]
5. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma.
Chi PD; Liu W; Chen H; Zhang JP; Lin Y; Zheng X; Liu W; Dai S
PLoS One; 2014; 9(3):e91080. PubMed ID: 24625581
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
Hicks LK; Cheung MC; Ding K; Hasan B; Seymour L; Le Maître A; Leighl NB; Shepherd FA
Cancer; 2009 Dec; 115(23):5516-25. PubMed ID: 19711465
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and prognosis in overweight and obese women with lung cancer receiving carboplatin-paclitaxel doublet chemotherapy.
Kashiwabara K; Yamane H; Tanaka H
Cancer Invest; 2013 May; 31(4):251-7. PubMed ID: 23607633
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
9. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
11. The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer.
Liu H; Gu X; Lv T; Wu Y; Xiao Y; Yuan D; Li Y; Song Y
J Cancer Res Ther; 2014; 10(2):239-43. PubMed ID: 25022372
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
Zhou DH; Lin LZ; Zhou YQ; Luo RC; Liu KF; Jia YJ; Chen JY; Niu XW; Su BR; Lu J; Wang ST
Ai Zheng; 2005 Oct; 24(10):1252-6. PubMed ID: 16219143
[TBL] [Abstract][Full Text] [Related]
13. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
Kogure Y; Ando M; Saka H; Chiba Y; Yamamoto N; Asami K; Hirashima T; Seto T; Nagase S; Otsuka K; Yanagihara K; Takeda K; Okamoto I; Aoki T; Takayama K; Yamasaki M; Kudoh S; Katakami N; Miyazaki M; Nakagawa K
J Thorac Oncol; 2013 Jun; 8(6):753-8. PubMed ID: 23575412
[TBL] [Abstract][Full Text] [Related]
14. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
15. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
[TBL] [Abstract][Full Text] [Related]
16. Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Mellema WW; van der Hoek D; Postmus PE; Smit EF
Lung Cancer; 2014 Oct; 86(1):73-7. PubMed ID: 25129368
[TBL] [Abstract][Full Text] [Related]
17. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials.
Mandrekar SJ; Schild SE; Hillman SL; Allen KL; Marks RS; Mailliard JA; Krook JE; Maksymiuk AW; Chansky K; Kelly K; Adjei AA; Jett JR
Cancer; 2006 Aug; 107(4):781-92. PubMed ID: 16847887
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study.
Hao B; Yu M; Sang C; Bi B; Chen J
Lipids Health Dis; 2018 Dec; 17(1):278. PubMed ID: 30522496
[TBL] [Abstract][Full Text] [Related]
19. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable Non-Small Cell Lung Cancer.
Zhang QL; Xing XZ; Li FY; Xing YJ; Li J
Oncol Res Treat; 2015; 38(10):496-502. PubMed ID: 26451776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
